510(k) Report

510(k) · Cleared

Cleared

BinaxNOW G6PD Test

K161364510(k) SpecialCleared Jun 17, 201631-day reviewClass II21 CFR 864.7360

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Alere Scarborough, Inc. · JBF Glucose-6-Phosphate Dehydrogenase (Erythrocytic), Screening

Cleared on Jun 17, 2016 as substantially equivalent to K080003 (Binax, Inc., 2008) after a 31-day review. Its family tree reaches back 2 generations to 1995.

Decided
Jun 17, 2016
Review
31 days
Class
Class II
Product code
JBF
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to K933934 (1995). No later device cites it as a predicate yet.

  1. Root · 2 generations backK933934 Glucose-6-Phosphate Dehydrogenase Deficiency Screening Test Kit NO.…Sigma Diagnostics, Inc. · 1995
  2. 1 generation backK080003 Binaxnow G6PD TestBinax, Inc. · 2008
  3. This deviceK161364 BinaxNOW G6PD TestAlere Scarborough, Inc. · 2016
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2K933934Glucose-6-Phosphate Dehydrogenase Deficiency Screening Test Kit NO. 202-aSigma Diagnostics, Inc.1995—
−1K080003Binaxnow G6PD TestBinax, Inc.2008—
0 (this device)K161364BinaxNOW G6PD TestAlere Scarborough, Inc.2016—
FIG. 1 — Lineage of K161364, 1995–2016Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in JBF? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new JBF device

  1. #1 K201049 Finder G6PDscore 4.0 · 1 generation · no Class I recall
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K080003Binaxnow G6PD Test
Summary page 4
…cytic glucose-6-phosphate dehydrogenase assay. (per 21 CFR 864.7360) CLASSIFICATION Class II PRODUCT CODE JBF PANEL Hematology PREDICATE DEVICES BinaxNOW® G6PD Test, K080003 BinaxNOW® G6PD Test Page 1 Special 510(k) Notification -…
Binax, Inc.2008—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 21 years and passes through 3 companies; a new generation was cleared every 13.3 years on median.
  • None of the 2 ancestors has a recall.

How does its category compare?

All JBF devices

JBF Glucose-6-Phosphate Dehydrogenase (Erythrocytic), Screening: FDA decisions, review times, recalls and adverse event reports over 20 years. 2016, this device’s year, is highlighted.

FDA decisions per year · JBF

1in 2022

2008: 12016: 12022: 1
2007high 1 (2008) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · JBF

Too few JBF 510(k)s in any year since 2007 to give a median.

Recalls per year · JBF

No recall names JBF since 2007.

Adverse event reports per year · JBF

4in 2023

2019: 12020: 12021: 12023: 4
2007high 4 (2023) · low 0 (2007)2025

MAUDE reports naming product code JBF, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20081—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20161—00
20170—00
20180—00
20190—01
20200—01
20210—01
20221—00
20230—04
20240—00
20250—00
20260—0—

What is it indicated for?

The BinaxNOW® G6PD (Glucose-6-Phosphate Dehydrogenase) Test is an in vitro enzyme chromatographic test for the qualitative detection of G6PD enzyme activity in human venous whole blood, collected in heparin or ethylenediaminetetraacetic acid (EDTA). The BinaxNOW® G6PD Test is a visual screening test used for differentiating normal from deficient G6PD activity levels in whole blood and is intended to aid in the identification of people with G6PD deficiency. Samples which generate deficient results should be assayed using a quantitative G6PD test method to verify the deficiency.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K161364: BinaxNOW G6PD Test.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K161364

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026